MARKET

NVAX

NVAX

Novavax Inc
NASDAQ
14.00
-0.06
-0.43%
After Hours: 14.02 +0.02 +0.16% 19:59 06/21 EDT
OPEN
14.01
PREV CLOSE
14.06
HIGH
14.43
LOW
13.59
VOLUME
23.83M
TURNOVER
0
52 WEEK HIGH
23.86
52 WEEK LOW
3.532
MARKET CAP
1.97B
P/E (TTM)
-4.4078
1D
5D
1M
3M
1Y
5Y
Novavax: New Chapter, Questions Remain
Seeking Alpha · 1d ago
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Quantum Corporation shares dipped 44.5% to $0.43 on Tuesday. The company reported worse-than-expected FY24 financial results and issued FY25 guidance below estimates. Reliance Global Group, Inc. Shares jumped 350% in today's mid-day session. NLS Pharmaceutics AG shares rose 166% on Monday.
Benzinga · 3d ago
Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine
NASDAQ · 4d ago
Novavax: Bird Flu And COVID-19 Headlines Trigger Rally
Novavax has seen a surge in stock price due to recent COVID-19 and bird flu vaccine developments. The company is making headlines with updates on their vaccine and potential FDA approval. Investors need to consider competition risks, but potential for Novavax to generate revenue.
Seeking Alpha · 4d ago
Jim Cramer Says He's 'Going To Have To Wait' On SoFi, But Recommends This 'Great Little Industrial Company'
Jim Cramer said he still can't recommend Twilio (NASDAQ:TWLO) on CNBC's "Mad Money Lightning Round" He said he prefers Constellation Energy Corporation. Cramer also recommended buying H.B. Fuller Company and Vistra Corp.
Benzinga · 5d ago
Weekly Report: what happened at NVAX last week (0610-0614)?
Weekly Report · 5d ago
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
NASDAQ · 06/15 05:54
Novavax Stockholders Elect Directors, Approve Executive Pay
TipRanks · 06/14 21:13
More
About NVAX
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

Webull offers Novavax Inc stock information, including NASDAQ: NVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVAX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVAX stock methods without spending real money on the virtual paper trading platform.